

6 February 2020

Australian Securities Exchange Limited  
40 Central Park  
152 – 158 St Georges Terrace  
PERTH WA 6000  
Attention: Anjuli Sinniah  
By email only: Anjuli.Sinniah@asx.com.au

Dear Madam,

#### **SECTION 708A CLEANSING NOTICE**

This notice is given by Zelira Therapeutics Ltd (**Zelira** or **the Company**) (ASX: ZLD) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

1. On 6 February 2020, the Company issued 2,000,000 fully paid ordinary shares (**Shares**) at an issue price of \$0.04 (4 cents) per Share following the conversion of unlisted options; and
2. The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
3. The Company is providing this notice under section 708A(5)(e) of the Corporations Act;
4. As at the date of this notice Zelira Therapeutics has complied with:
  - a. The provisions of Chapter 2M of the Corporations Act as they apply to Company; and
  - b. Section 674 of the Corporations Act; and
5. As at the date of this notice, there is no information that is “excluded information” (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by Zelira.

Please see the Appendix 2A dated 6 February 2020 for details of the share issue.

Yours sincerely



Tim Slate  
**Company Secretary**

